# OnCo record oesophageal-squamous-cell-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "oesophageal-squamous-cell-carcinoma" ;
  schema:name "Oesophageal squamous cell carcinoma"@en ;
  schema:alternateName "Esophageal squamous cell carcinoma"@en, "ESCC"@en, "Oesophageal SCC"@en ;
  schema:description "Squamous cell carcinoma of the oesophagus, the world's commonest form, is linked to smoking, alcohol and very hot drinks and sits in the upper and middle gullet. It is treated with chemoradiation, with or without surgery, and immunotherapy has recently joined chemotherapy for advanced disease."@en ;
  schema:url <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Esophageal_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Esophageal_cancer> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cross-nejm-2012/>, <https://onco.cc/key-papers/paper-checkmate-648-nejm-2022/>, <https://onco.cc/key-papers/paper-keynote-590-lancet-2021/>, <https://onco.cc/key-papers/paper-checkmate-577-nejm-2021/> ;
  onco:pipeline <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/tislelizumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/trials/cross/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-577/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/checkmate-648/>, <https://onco.cc/trials/keynote-590/>, <https://onco.cc/technologies/smoking-cessation-after-diagnosis/>, <https://onco.cc/technologies/alcohol-reduction-labelling/> .